Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Q3 net loss widens to $144.8 million as R&D spending rises

Negative Impact 3 of 5 earnings

Structure Therapeutics reported a third-quarter 2026 net loss of $144.8 million, up from $65.7 million a year earlier, as research and development expenses rose to $134.6 million from $59.0 million. The company had $1.2 billion in cash, cash equivalents and short-term investments at September 30, 2026, which it says will fund projected operations and key clinical milestones through 2028.

Key points

  • Q3 2026 net loss was $144.8 million, compared with $65.7 million in Q3 2025.
  • R&D expenses were $134.6 million, up from $59.0 million, mainly due to clinical trial costs.
  • Cash, cash equivalents and short-term investments were $1.2 billion at September 30, 2026, down from $1.3 billion at June 30, 2026.
  • Topline data from the Phase 3 ACCOMPLISH program for aleniglipron are expected in the second half of 2028.

The filing

CompanyStructure Therapeutics Inc. (GPCR)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:11 PM ET
Accession number0001104659-26-124494

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.